Login / Signup

Use of sildenafil and other phosphodiesterase type 5 inhibitors among pregnant women in Scandinavia.

Carolyn E CestaSilvia Segovia ChacónAnders EngelandAnne BroePer DamkierKari FuruHelle KielerPär Karlsson
Published in: Acta obstetricia et gynecologica Scandinavica (2021)
Few women used PDE5 inhibitors in outpatient settings before or during pregnancy in the Scandinavian countries in the last decades. Only a small proportion had a diagnosis for pulmonary arterial hypertension, suggesting off-label use in the remaining users. Use was predominantly in mothers over age 35 years. The safety of fetal exposure to sildenafil and other PDE5 inhibitors in pregnancy has not been established. As maternal age continues to increase and additional uses of PDE5 inhibitors are investigated, the safety of these drugs in pregnancy should be thoroughly evaluated.
Keyphrases